World's Best Scientists 2026 revealed!
EMBO Molecular Medicine
H-index 64

EMBO Molecular Medicine

1757-4676

Published by: Wiley

https://www.embopress.org/journal/17574684

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 254 331 264 48

Additional Metrics

Number of Best Scientists*: 1165
Documents by Best Scientists*: 601
Top 100 Ranked Scientists*: 38
SCIMAGO H-index: 151
SCIMAGO SJR: 3.571
Impact Factor: 8.3

Overview

Top Research Topics at Embo Molecular Medicine?

The topics of Cancer research, Cell biology, Immunology, Internal medicine and Endocrinology are the focal point of discussions in the journal. The journal explores issues in Cancer research which can be linked to other research areas like Cancer cell, Cancer, Metastasis, Pathology and Stem cell. Presentations on Cell biology include those discussing Mitochondrion and Signal transduction.

The research on Immunology discussed in it draws on the closely related field of Disease. Studies on Internal medicine discussed in Embo Molecular Medicine link to the field of Oncology.

  • Cancer research (27.81%)
  • Cell biology (18.49%)
  • Immunology (18.15%)

What are the most cited papers published in the journal?

  • The amyloid hypothesis of Alzheimer's disease at 25 years (2562 citations)
  • MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (1202 citations)
  • Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors (535 citations)

Research areas of the most cited articles at Embo Molecular Medicine:

The most cited publications primarily tackle Cancer research, Immunology, Cell biology, Internal medicine and Pathology. The study of Cancer research in the published papers encompasses disciplines such as Metastasis, as well as fields such as Cancer cell, all of which overlap with one another. The journal articles with studies in Immunology featured incorporate elements of Disease and Transplantation.

What topics the last edition of the journal is best known for?

  • Gene
  • Cancer
  • Internal medicine

The previous edition focused in particular on these issues:

The journal is mainly concerned with subjects like Cancer research, Cell biology, Disease, Immune system and Cancer. The Cancer research research dealing mostly with Angiogenesis is the focus of Embo Molecular Medicine. The majority of Cell biology studies are focused on the issues of Mitochondrion.

The studies on Disease discussed can also contribute to research in the domains of Biomarker (medicine), Immunology and Bioinformatics. Research in Biomarker (medicine) discussed is concerned with the study of Internal medicine as a whole. The Cancer study tackled is a key component of adjacent topics in the area of Lung cancer.

The most cited articles from the last journal are:

  • Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. (22 citations)
  • A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2 (21 citations)
  • Delivery of oligonucleotide-based therapeutics: challenges and opportunities. (19 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Embo Molecular Medicine (based on the number of publications) are:

  • Luigi Naldini (12 papers) published 2 papers at the last edition,
  • Bart De Strooper (12 papers) absent at the last edition,
  • Claude Libert (11 papers) published 1 paper at the last edition, 1 less than at the previous edition,
  • Christian Haass (11 papers) absent at the last edition,
  • Massimo Zeviani (10 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Embo Molecular Medicine (based on the number of publications) are:

  • French Institute of Health and Medical Research (86 papers) published 8 papers at the last edition, 4 more than at the previous edition,
  • German Cancer Research Center (52 papers) published 7 papers at the last edition, 2 more than at the previous edition,
  • Ludwig Maximilian University of Munich (51 papers) published 11 papers at the last edition, 5 more than at the previous edition,
  • Max Planck Society (49 papers) published 8 papers at the last edition, 6 more than at the previous edition,
  • Boston Children's Hospital (48 papers) published 7 papers at the last edition, 3 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 0.00% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 30.82% were posted by at least one author from the top 10 institutions publishing in the journal. Another 14.47% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 23.90% of all publications and 30.82% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Pathways Opening

A section exploring career opportunities and advancement for those involved in the research areas discussed in this article seems to be missing. This would be particularly valuable for students and emerging researchers who are reading this article. The exploration could also include a discussion around the types of degrees required to engage in this kind of research and where those programs can be found. This could appear as such: **Career Opportunities in the Field of Molecular Medicine** The research fields discussed in Embo Molecular Medicine, such as Cell biology, Immunology, Internal medicine, and Endocrinology, provide a variety of career pathways in medical research. These careers often require advanced degrees or specific certifications. For those interested in expanding their knowledge and qualifications in this complex field, it's essential to select a reputable and rigorous degree program. For instance, those striving to work in patient care alongside their research may find value in pursuing a Nurse Practitioner degree, specifically from universities renowned for their strong emphasis on research. One such program - known to provide students with extensive skills and knowledge essential for both patient care and research - is among the best nurse practitioner programs in Ohio. This comprehensive course gives students a solid foundation in critical healthcare principles while also focusing on the research aspect, thus, fostering a dynamic blend of theory and practice. As the molecular medicine field continues to grow, those with a combined background in patient care and research will find themselves very well suited to the evolving landscape of modern healthcare. By obtaining quality education and training, aspiring practitioners and researchers can make meaningful contributions to the medical research field, particularly in the research areas highlighted in this journal.

Top Publications

  • Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected.

    Marc Suárez-Calvet;Thomas K Karikari;Nicholas J Ashton;Juan Lantero Rodríguez

    (2020)
    375 Citations
  • Sepsis therapies: learning from 30 years of failure of translational research to propose new leads.

    Jean‐Marc Cavaillon;Mervyn Singer;Tomasz Skirecki

    (2020)
    313 Citations
  • Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology.

    Annerieke Sierksma;Ashley Lu;Renzo Mancuso;Nicola Fattorelli

    (2020)
    291 Citations
  • Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.

    Justin Stebbing;Venkatesh Krishnan;Stephanie de Bono;Silvia Ottaviani

    (2020)
    270 Citations
  • Sarcoma treatment in the era of molecular medicine

    Thomas G. P. Grunewald;Thomas G. P. Grunewald;Thomas G. P. Grunewald;Marta Alonso;Sofia Avnet;Ana Banito

    (2020)
    225 Citations
  • Blood-based biomarkers for Alzheimer's disease.

    Antoine Leuzy;Niklas Mattsson-Carlgren;Sebastian Palmqvist;Shorena Janelidze

    (2021)
    190 Citations
  • Predicting antimicrobial resistance in Pseudomonas aeruginosa with machine learning-enabled molecular diagnostics.

    Ariane Khaledi;Aaron Weimann;Monika Schniederjans;Ehsaneddin Asgari

    (2020)
    183 Citations
  • The rapidly evolving view of lysosomal storage diseases

    Giancarlo Parenti;Diego L Medina;Andrea Ballabio

    (2021)
    165 Citations
  • Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia.

    Lara Gibellini;Sara De Biasi;Annamaria Paolini;Rebecca Borella

    (2020)
    159 Citations
  • Why does Japan have so few cases of COVID-19?

    Akiko Iwasaki;Akiko Iwasaki;Nathan D Grubaugh

    (2020)
    151 Citations

Related Online Degrees & Career Pathways

For those considering a medical career in the USA, exploring related online degrees can open diverse pathways. Many aspiring healthcare professionals start with specialized programs such as adn to np programs online, which offer a streamlined bridge from nursing to becoming a nurse practitioner. These options provide flexibility and help meet growing healthcare demands.

Another route gaining popularity is the direct entry msn online programs, designed for individuals without a nursing background who want to fast-track their MSN degrees. These programs are ideal for career changers seeking advanced nursing roles without following traditional pathways.

Deciding between online RN-to-BSN programs can be challenging. Comparing options like capella vs chamberlain rn to bsn highlights differences in curriculum, cost, and flexibility, assisting students in selecting the best fit for their goals and lifestyles.

Affordability is also key when advancing your education. Many students benefit from exploring online bsn programs that offer quality education without the high price tag, making career advancement more accessible across the country.

Best Scientists Contributing to This Journal

Recently Published Articles